Cancer Immunotherapy Market
Cancer Immunotherapy Market (Therapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines; Therapeutic Areas - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancers; End Users - Hospitals, ASC’s (Ambulatory Surgical Centers), and Cancer Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Press Release :
Global Cancer Immunotherapy Market: Snapshot
The global cancer immunotherapy market is prognosticated to encounter a high rate of development over the coming years, inferable from the rise in number of people suffering from different types of cancers. In 2015, the global cancer immunotherapy market was esteemed at US$37.50 bn. its revenue is anticipated to progress at an extremely solid CAGR of 14.6% inside a conjecture period from 2016 to 2024, the global cancer immunotherapy market is required to achieve US$124.88 bn before the finish of 2024.
Increased Efficiency Over Traditional Methods to Bolster Market Growth
As far as the treatment choices for cancer are concerned, cancer immunotherapy is foreseen to make genuine progress because of its greater efficiency over traditional treatment technique. The market is anticipated to demonstrate a high development rate over the upcoming years as well, because of an extremely promising treatment methods in the pipelines. In any case, the global cancer immunotherapy market is expected to be hindered by factors, for example, the increased level of steady loss inside the development cycles of its various product types, and overall absence of awareness about immunotherapy as a superior choice to conventional treatment in numerous regions of the world.
Cost-Effective Nature of Treatment Makes it Popular Among Patients
In terms of types of therapies, the global cancer immunotherapy market can be segmented into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Among these, monoclonal antibodies have so far been the leading choice of treatment methods for a large segment of the global healthcare industry, giving it a high lead over other segments. This therapy type has been more affordable than the other types, allowing it to gain greater popularity. However, the global cancer immunotherapy market is expected to witness a spike in the demand for immune checkpoint inhibitors due to their greater percentages of success rates and higher overall efficiency.
In terms of area of therapy, the global cancer immunotherapy market is divided into blood cancer, prostate cancer, melanoma, breast cancer, lung cancer, colorectal cancer, and other minor areas. Of these, breast cancer has been the leading area of immunotherapy. Lung cancer is also showing a very high increase in rate of demand owing to the growing population of smokers and the higher overall air pollution in urban areas.
Rising Awareness Among People to Fuel Growth in Europe
Geography-wise, the global cancer immunotherapy market is divided into Europe, North America, Asia Pacific, and rest of the world. The market's past has pretty much been established inside the created economies of the world. Europe and North America have been a base for a few of the best level innovative work in the global cancer immunotherapy market up until this point. The two regions have likewise represented a lot of demand for cancer immunotherapy inferable from a more awareness in population and improved healthcare care, globally.
The key players operating in the global cancer immunotherapy market are Amgen, Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline Plc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, Janssen Biotech, Inc., Merck & Co., Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.
Strategies in Cancer Immunotherapy Market Expand Canvas for Oncology Personalized Medicine
Strides in cancer immunotherapy have redefined the standard of care in relation to both survival rates and quality of life. Immune checkpoint inhibitors and T lymphocytes overcome the traditional approaches to cancer therapies such as chemotherapy, radiation, and surgery. A growing understanding of cancer immunology, particularly how effector T cells recognize tumor antigens, is the key underpinning for this. Tumor immune evasion comprises, inter alia, different ways for T cell exhaustion; hence, ongoing research efforts focus on new strategies of immunotherapy that can counteract cancer immune evasion. New directions in the cancer immunotherapy market have stemmed from immune checkpoint inhibitors. In recent years, CTLA-4 and PD-1 have become T cell immune checkpoints of interest, and are expected to transform the standard of care in cancer immunotherapy. However, current approaches in cancer immunotherapy are still in preliminary stages, due to recalcitrant nature of immune-related adverse events. These events pose substantial challenges in predicting, diagnosing, and treating cancer types. Such events have been observed notably in melanoma and lung cancer. This is despite the fact that a number of molecular therapies have been approved by the FDA. Another rapidly emerging development avenue likely to attract lodes of investments in the cancer immunotherapy market is vaccination therapy. However, their role in preventing cancer is debatable and lacks evidence, which implies they are largely therapeutic.
The currently emerging coronavirus pandemic caused by SARS-CoV-2 has posed serious and unprecedented threats to public health across the world. Capable of rapid transmission, it has resulted in massive mortality and morbidity. Several restrictions have been imposed by governments to prevent the spread of the virus, thereby, crippling economic activities on various levels. Numerous non-essential economic activities and firm production have suffered. As a fallout, several businesses from across different industries were forced to shift to new business models, notably digital models and industrial automation, to keep them afloat. New agile models have gained attention by contract research organizations, research community, and lifesciences industries in major economies of the world. All these are shaping the contours of the market dynamics in the post-pandemic world.
Global Cancer Immunotherapy Market: Overview
The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market.
The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region. Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market.
Global Cancer Immunotherapy Market: Trends and Drivers
The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market’s growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years.
However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market. With many types and subtypes of cancer, having a single mode of treatment method is impossible, increasing the attrition rates of new drugs and treatments. Only a handful of contenders in the pipeline pass through the phase III trials and the rest are considered to be inefficient. This is yet another challenge faced by players in the market.
Global Cancer Immunotherapy Market: Segmentation
On the basis of therapeutic area, the market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. By end users, the global cancer immunotherapy market is segmented into ASC’s (ambulatory surgical centers), hospitals, clinics, and cancer research centers. Hospitals are expected to be the leading segment in the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Asia Pacific is poised to witness significant growth in the market.
Key Players Mentioned in this Report are:
The report provides studies key players operating in the market. Some of the key players in the global cancer immunotherapy market are: F.Hoffmann-La Roche Ltd., AstraZenca Plc, Eli Lilly and Company, Amgen, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Janssen Biotech, Inc., Merck & Co., Inc., Sanofi, Takeda Pharmaceuticals, and Spectrum Pharmaceuticals, Inc.
The report segments the global cancer immunotherapy market as:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments